Your browser doesn't support javascript.
loading
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
van der Zanden, Loes F M; Vermeulen, Sita H; Oskarsdottir, Arna; Maurits, Jake S F; Diekstra, Meta H M; Ambert, Valentin; Cambon-Thomsen, Anne; Castellano, Daniel; Fritsch, Achim; Garcia Donas, Jesus; Guarch Troyas, Rosa; Guchelaar, Henk-Jan; Hartmann, Arndt; Hulsbergen-van de Kaa, Christina; Jaehde, Ulrich; Junker, Kerstin; Martinez-Cardus, Anna; Masson, Gisli; Oosterwijk-Wakka, Jeannette; Radu, Marius T; Rafnar, Thorunn; Rodriguez-Antona, Cristina; Roessler, Max; Ruijtenbeek, Rob; Stefansson, Kari; Warren, Anne; Wessels, Lodewyk; Eisen, Tim; Kiemeney, Lambertus A L M; Oosterwijk, Egbert.
Afiliação
  • van der Zanden LFM; Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
  • Vermeulen SH; Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
  • Oskarsdottir A; deCODE Genetics/Amgen, Reykjavik, Iceland.
  • Maurits JSF; Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
  • Diekstra MHM; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
  • Ambert V; University of Medicine and Pharmacy Carol Davila, Bucaresti, Romania, Bucuresti, Romania.
  • Cambon-Thomsen A; Epidemiology and analyses in public health, Joint Unit 1027, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III Paul Sabatier, Faculty of Medicine, Toulouse, France.
  • Castellano D; Medical Oncology Department, Hospital Universitario 12 de Octubre, I+12 Research Institute, (CiberOnc), Madrid, Spain.
  • Fritsch A; Institute of Pharmacy, Clinical Pharmacy, University of Bonn, Bonn, Germany.
  • Garcia Donas J; Medical Oncology, HM Hospitales-Centro Integral Oncológico HM Clara Campal, Madrid, Spain.
  • Guarch Troyas R; Anatomía Patológica, Complejo Hospitalario de Navarra, Pamplona, Spain.
  • Guchelaar HJ; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
  • Hartmann A; Department of Pathology, University Erlangen-Nürnberg, Erlangen, Germany.
  • Hulsbergen-van de Kaa C; Department of Pathology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
  • Jaehde U; Institute of Pharmacy, Clinical Pharmacy, University of Bonn, Bonn, Germany.
  • Junker K; Clinic of Urology and Paediatric Urology, Saarland University, Homburg, Germany.
  • Martinez-Cardus A; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Catalonia, Spain.
  • Masson G; deCODE Genetics/Amgen, Reykjavik, Iceland.
  • Oosterwijk-Wakka J; Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
  • Radu MT; University of Medicine and Pharmacy Carol Davila, Bucaresti, Romania, Bucuresti, Romania.
  • Rafnar T; deCODE Genetics/Amgen, Reykjavik, Iceland.
  • Rodriguez-Antona C; Hereditary Endorine Cancer Group, Spanish National Cancer Research Centre (CNIO) and Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain.
  • Roessler M; CESAR central office, CESAR Central European Society for Anticancer Drug Research-EWIV, Vienna, Austria.
  • Ruijtenbeek R; PamGene International B.V., 's-Hertogenbosch, The Netherlands.
  • Stefansson K; deCODE Genetics/Amgen, Reykjavik, Iceland; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavík, Iceland.
  • Warren A; Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK.
  • Wessels L; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Eisen T; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK.
  • Kiemeney LALM; Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands. Electronic address: Bart.Kiemeney@radboudumc.nl.
  • Oosterwijk E; Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Urol Oncol ; 35(8): 529.e9-529.e16, 2017 08.
Article em En | MEDLINE | ID: mdl-28385611
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Biomarcadores Tumorais / Terapia de Alvo Molecular / Neoplasias Renais Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Urol Oncol Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Biomarcadores Tumorais / Terapia de Alvo Molecular / Neoplasias Renais Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Urol Oncol Ano de publicação: 2017 Tipo de documento: Article